bpc-157 fda status or approved or banned 2026 The internet says is -- the says something more nuanced. At Moonshot Medical in Park Ridge, IL, we provide honest, current guidance on peptide therapy through licensed compounding pharmacies 83% of peptide-aware Americans want

That is marketing

BPC-157s anti-inflammatory properties help calm acute bursitis relatively quickly

In preclinical studies published in Endocrinology, researchers found that chronic administration of AOD-9604 reduced body weight and body fat in obese mice while increasing beta-3 adrenergic receptor expression to levels comparable with lean mice

Research also documents GHK-Cu's effects on angiogenesis markers in tissue models with limited vascular supply

What the evidence supports: BPC-157 consistently improves tendon healing outcomes in animal models across multiple tissue types and injury models TB-500 accelerates wound healing and tissue repair in preclinical studies with measurable improvements in re-epithelialization, collagen deposition, and angiogenesis GHK-Cu enhances collagen synthesis and modulates thousands of genes involved in tissue repair GHRP-2 shifts macrophage polarization favorably in a rotator cuff tear model Relaxin-2 eliminates capsular fibrosis in a frozen shoulder mouse model No significant toxicity has been identified in preclinical BPC-157 studies What remains uncertain: Whether animal study results translate to equivalent human outcomes for shoulder conditions specifically Optimal dosing for human shoulder injuries (all protocols are extrapolated from animal data and clinical observation) Long-term safety with repeated use Whether peptides meaningfully reduce rotator cuff retear rates after surgical repair in humans How peptide therapy compares to established treatments like PRP in controlled human studies Potential interactions with medications commonly used by shoulder pain patients What we need: Randomized controlled trials of BPC-157 and TB-500 for specific shoulder conditions in humans Head-to-head comparisons of peptide therapy versus established treatments Long-term safety data from monitored human use Standardized dosing protocols based on human pharmacokinetic data Studies combining peptides with rehabilitation to assess synergistic effects The preclinical evidence is compelling

doi: 10.1002/art.34339 45 CrottiCAgapeEBeccioliniABiggioggeroMFavalliEG